-Substituted -amino acids, -substituted -amino acid derivatives, and -substituted -amino acid analogs and (bio)isosteres and their use as chemotherapeutic agents are disclosed. The -substituted -amino acid derivatives and -substituted -amino acid analogs and (bio)isosteres are selective LAT1/4F2hc substrates and exhibit rapid uptake and retention in tumors expressing the LAT1/4F2hc transporter. Methods of synthesizing the -substituted -amino acid derivatives and -substituted -amino acid analogs and methods of using the compounds for treating cancer are also disclosed. The -substituted -amino acid derivatives and -substituted -amino acid analogs exhibit selective uptake in tumor cells expressing the LAT1/4F2hc transporter and accumulate in cancerous cells when administered to a subject in vivo. The -substituted -amino acid derivatives and -substituted -amino acid analogs and (bio)isosteres exhibit cytotoxicity toward several tumor types.

A method of treating a siliciclastic, hydrocarbon-bearing formation includes contacting the hydrocarbon-bearing formation with a composition comprising solvent and a fluorinated amine oxide. The method can provide siliciclastic, hydrocarbon-bearing formations treated according to the method.

A method of treating a siliciclastic, hydrocarbon-bearing formation includes contacting the hydrocarbon-bearing formation with a composition comprising solvent and a fluorinated amine oxide. The method can provide siliciclastic, hydrocarbon-bearing formations treated according to the method.

The invention provides novel chemical entities based on sugar alcohols. These new chemical entities are biocompatible and biodegradable. The molecules can be made in a single and pure form. The molecular weights of these molecules range from small (<1000 Da) to large (1000-120,000 Da). The sugar alcohol-based molecules can have functional groups throughout the molecule for crosslinking compounds, such as the preparation of antibody-drug conjugates, or to facilitate the delivery of therapeutic proteins, peptides, siRNA, and chemotherapeutic drugs. Also provided are new conjugate entities prepared through sugar alcohol molecules. Methods of synthesizing sugar alcohol-based molecules and conjugates are also within the scope of the invention.

The invention provides novel chemical entities based on sugar alcohols. These new chemical entities are biocompatible and biodegradable. The molecules can be made in a single and pure form. The molecular weights of these molecules range from small (<1000 Da) to large (1000-120,000 Da). The sugar alcohol-based molecules can have functional groups throughout the molecule for crosslinking compounds, such as the preparation of antibody-drug conjugates, or to facilitate the delivery of therapeutic proteins, peptides, siRNA, and chemotherapeutic drugs. Also provided are new conjugate entities prepared through sugar alcohol molecules. Methods of synthesizing sugar alcohol-based molecules and conjugates are also within the scope of the invention.

-Substituted -amino acids, -substituted -amino acid derivatives, and -substituted -amino acid analogs and (bio)isosteres and their use as chemotherapeutic agents are disclosed. The -substituted -amino acid derivatives and -substituted -amino acid analogs and (bio)isosteres are selective LAT1/4F2hc substrates and exhibit rapid uptake and retention in tumors expressing the LAT1/4F2hc transporter. Methods of synthesizing the -substituted -amino acid derivatives and -substituted -amino acid analogs and methods of using the compounds for treating cancer are also disclosed. The -substituted -amino acid derivatives and -substituted -amino acid analogs exhibit selective uptake in tumor cells expressing the LAT1/4F2hc transporter and accumulate in cancerous cells when administered to a subject in vivo. The -substituted -amino acid derivatives and -substituted -amino acid analogs and (bio)isosteres exhibit cytotoxicity toward several tumor types.

The present invention relates to a perfluoropolyether group-containing silane compound represented by formula (1): Rf-X.sup.1X.sup.2NQ.sub.kT.sub.2-k (1), and a method for preparing the same. The present invention also relates to a perfluoropolyether group-containing silane compound represented by formula (2), ##STR00001##
and a method for preparing the same. The present invention also relates to a perfluoropolyether group-containing silane compound represented by formula (3), ##STR00002##
and a method for preparing the same. The perfluoropolyether group-containing silane compound of the present invention can be used for a surface treatment agent so that the substrates such as glass etc processed by the surface treatment agent are excellent in anti-fouling, anti-fingerprint, scrape resistant and abrasion resistant performances. Moreover, the preparation method of each of the compounds of the present invention is simple in process, easy to operate and implement.

An amphiphilic lipid including a tertiary amine N-oxide group, a liposomal drug-delivery system, and a use of the amphiphilic lipid are provided. The amphiphilic lipid is a compound shown in a formula I, where R and R each are independently selected from C.sub.1-C.sub.4 alkyl and X is a hydrophobic unit. The amphiphilic lipid can be used alone or together with the traditional phospholipid to prepare a liposomal drug-delivery system. The liposomal drug-delivery system can significantly prolong the blood circulation time of a drug and increase the accumulation and penetration of a drug in target tissues, resulting in a significantly-improved therapeutic effect.

An amphiphilic lipid including a tertiary amine N-oxide group, a liposomal drug-delivery system, and a use of the amphiphilic lipid are provided. The amphiphilic lipid is a compound shown in a formula I, where R and R each are independently selected from C.sub.1-C.sub.4 alkyl and X is a hydrophobic unit. The amphiphilic lipid can be used alone or together with the traditional phospholipid to prepare a liposomal drug-delivery system. The liposomal drug-delivery system can significantly prolong the blood circulation time of a drug and increase the accumulation and penetration of a drug in target tissues, resulting in a significantly-improved therapeutic effect.

Disclosed are benzoate derivatives. Provided is a compound having a formula selected from the group consisting of following structures. The compound can be used for quality control over a 2-(diethylamino)ethyl 2-acetoxybenzoate hydrochloride product, and also for inflammation diminishment. ##STR00001##